Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christophe Borg

Showing results (191-200 of 224) with videos related to

Pageof 23
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2018
Clinical Validity of HPV Circulating Tumor DNA in Advanced Anal Carcinoma: An Ancillary Study to the Epitopes-HPV02 TrialAlice Bernard-Tessier, Emmanuelle Jeannot, David Guenat, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|March 27, 2019
Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 studyYung-Jue Bang, Yoon-Koo Kang, Daniel V Catenacci, et al.
Experimental Hematology & Oncology|July 21, 2023
DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: a multicenter propensity score-matching studyStefano Kim, Véronique Vendrely, Angélique Saint, et al.
Journal of Translational Medicine|March 3, 2005
Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trialBernard Escudier, Thierry Dorval, Nathalie Chaput, et al.
British Journal of Cancer|December 15, 2023
Primary resistance to immunotherapy in patients with a dMMR/MSI metastatic gastrointestinal cancer: who is at risk? An AGEO real-world studyClémence Flecchia, Edouard Auclin, Emily Alouani, et al.
European Journal of Cancer (Oxford, England : 1990)|February 7, 2026
Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): Results from the GASPAR phase 2 studyMélanie Dos Santos, Justine Lequesne, Guillaume Piessen, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|April 13, 2020
Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2Masatoshi Kudo, Peter R Galle, Josep M Llovet, et al.
The Lancet. Gastroenterology & Hepatology|January 19, 2020
Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 studyPhilip A Philip, Jill Lacy, Fabienne Portales, et al.
Nature Medicine|August 10, 2023
First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trialMarion Thibaudin, Jean-David Fumet, Benoist Chibaudel, et al.
The Lancet. Oncology|April 16, 2021
Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trialThierry Conroy, Jean-François Bosset, Pierre-Luc Etienne, et al.
Pageof 23

Showing results (191-200 of 224) with videos related to

Sort By:
Pageof 23
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2018
Clinical Validity of HPV Circulating Tumor DNA in Advanced Anal Carcinoma: An Ancillary Study to the Epitopes-HPV02 TrialAlice Bernard-Tessier, Emmanuelle Jeannot, David Guenat, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|March 27, 2019
Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 studyYung-Jue Bang, Yoon-Koo Kang, Daniel V Catenacci, et al.
Experimental Hematology & Oncology|July 21, 2023
DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: a multicenter propensity score-matching studyStefano Kim, Véronique Vendrely, Angélique Saint, et al.
Journal of Translational Medicine|March 3, 2005
Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trialBernard Escudier, Thierry Dorval, Nathalie Chaput, et al.
British Journal of Cancer|December 15, 2023
Primary resistance to immunotherapy in patients with a dMMR/MSI metastatic gastrointestinal cancer: who is at risk? An AGEO real-world studyClémence Flecchia, Edouard Auclin, Emily Alouani, et al.
European Journal of Cancer (Oxford, England : 1990)|February 7, 2026
Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): Results from the GASPAR phase 2 studyMélanie Dos Santos, Justine Lequesne, Guillaume Piessen, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|April 13, 2020
Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2Masatoshi Kudo, Peter R Galle, Josep M Llovet, et al.
The Lancet. Gastroenterology & Hepatology|January 19, 2020
Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 studyPhilip A Philip, Jill Lacy, Fabienne Portales, et al.
Nature Medicine|August 10, 2023
First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trialMarion Thibaudin, Jean-David Fumet, Benoist Chibaudel, et al.
The Lancet. Oncology|April 16, 2021
Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trialThierry Conroy, Jean-François Bosset, Pierre-Luc Etienne, et al.
Pageof 23